Brief: HCW Biologics Shows Paper On Potential Of Cancer Immunotherapeutic
24/08/2021 13:29
Aug 24 (Reuters) - HCW Biologics Inc HCWB.O :
* HCW BIOLOGICS SHOWCASES SCIENTIFIC PAPER IN MOLECULAR
THERAPY
HIGHLIGHTING POTENTIAL OF HCW9218 AS NOVEL, BIFUNCTIONAL CANCER
IMMUNOTHERAPEUTIC
* HCW BIOLOGICS - INVESTIGATIONAL NEW DRUG APPLICATION FOR
CHEMOTHERAPY-REFRACTORY PANCREATIC CANCER EXPECTED TO BE FILED
BY YEAR-END 2021
Source text for Eikon: ID:nGNXccJMCX
Further company coverage: HCWB.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Hcw Biologics
See all newsBrief: Hcw Biologics Maintains Momentum Toward Completion Of Ind Application For Clinical Study To Evaluate Lead T-Cell Engager In Solid Tumors
Brief: HCW Biologics Registers Resale Of Up To 1.81 Mln Shares Of Common Stock By Selling Stockholder- SEC Filing
NASDAQ RESUMED AT 10:34 AM
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 10:29 AM
NASDAQ RESUMED AT 10:29 AM